Reassessment of histological specimens of salivary gland carcinomas is associated with a change of primary diagnosis in a significant number of patients. The authors evaluated the relation between reclassification/verification of histological diagnosis and the clinical course of parotid gland carcinomas. Histological and immunohistochemical examinations of 111 specimens of parotid gland carcinomas operated on during the years 1992-2010 were revised and in some cases supplemented with cytogenetic tests (FISH), to verify the diagnosis and potentially reclassify the tumours. Analysis of the clinical documentation and follow-up data of patients whose diagnosis was changed was then carried out. The prognostic factors taken into account in the evaluation of the clinical course included the T and N stage, the tumour grade and the extent of resection. The primary diagnosis was changed on review in 28 patients (25.2 %). In 16 patients, the change involved a different histological type of cancer. In six cases, what was thought to be a primary salivary gland cancer was reclassified as a secondary tumour. In four other cases, the change was made from a malignant to a benign tumour and in one case to a non-neoplastic lesion (necrotizing sialometaplasia). Additionally, in two patients with carcinoma ex pleomorphic adenoma, the malignant component was found to be of in situ type. A potentially atypical clinical course was observed in 4 out of 28 patients whose diagnosis was changed. In the case of 2 patients, the course of disease was more aggressive (dissemination, death) than predicted and less aggressive in rest of the patients. Histological reclassification/verification of parotid gland carcinomas can explain the cause of an atypical clinical course in some patients and sometimes enables doctors to implement a change in therapy.

Department of Otolaryngology Medical University of Gdańsk Gdańsk Poland

Department of Pathology Charles University Prague Faculty of Medicine in Pilsen Pilsen Czech Republic

Department of Pathomorphology Medical University of Gdańsk Gdańsk Poland

Zobrazit více v PubMed

Luna MA. Salivary glands. In: Pilch BZ, editor. Head and neck surgical pathology. Philadelphia: Lippincott Williams & Wilkins; 2000.

Thackray AC, Sobin LH (1972) Histological typing of salivary gland tumours. World Health Organization. International classification of tumours. The organization, Geneva

Seifert G, Sobin LH. World Health Organization. International classification of tumours. Berlin: Springer; 1991. Histological typing of salivary gland tumours.

Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours. Lyon: IARC; 2005. World Health Organization classification of tumours.

Gnepp DR. Salivary gland tumor “wishes” to add to the next WHO tumor classification: sclerosing polycystic adenosis, mammary analogue secretory carcinoma, cribriform adenocarcinoma of the tongue and other sites, and mucinous variant of myoepithelioma. Head Neck Pathol. 2014;8:42–49. doi: 10.1007/s12105-014-0532-x. PubMed DOI PMC

van der Wal JE, Snow GB, van der Waal I. Histological reclassification of 101 intraoral salivary gland tumours (new WHO classification) J Clin Pathol. 1992;45:834–835. doi: 10.1136/jcp.45.9.834. PubMed DOI PMC

van der Wal JE, Leverstein H, Snow GB, Kraaijenhagen HA, van der Waal I. Parotid gland tumors: histologic reevaluation and reclassification of 478 cases. Head Neck. 1998;20:204–207. doi: 10.1002/(SICI)1097-0347(199805)20:3<204::AID-HED4>3.0.CO;2-4. PubMed DOI

Godballe C, Schultz JH, Krogdahl A, Møller-Grøntved A, Johansen J. Parotid carcinoma: impact of clinical factors on prognosis in a histologically revised series. Laryngoscope. 2003;113:1411–1417. doi: 10.1097/00005537-200308000-00028. PubMed DOI

Majewska H, Skálová A, Stodulski D, Klimková A, Steiner P, Stankiewicz C, Biernat W. Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement. Virchows Arch. 2015;466:245–254. doi: 10.1007/s00428-014-1701-8. PubMed DOI PMC

Skálová A, Vanecek T, Simpson RH, Vazmitsel MA, Majewska H, Mukensnabl P, Hauer L, Andrle P, Hosticka L, Grossmann P, Michal M. CRTC1-MAML2 and CRTC3-MAML2 fusions were not detected in metaplastic Warthin tumor and metaplastic pleomorphic adenoma of salivary glands. Am J Surg Pathol. 2013;37:1743–1750. doi: 10.1097/PAS.0000000000000065. PubMed DOI

Wittekind C, Meyer HJ. Head neck cancer. In: Sobin LH, Gospodarowicz MK, Wittekind C, editors. UICC TNM classification of malignant tumours. 7. New York: Wiley; 2009. pp. 23–60.

Bjørndal K, Krogdahl A, Therkildsen MH, Overgaard J, Johansen J, Kristensen CA, Homøe P, Sørensen CH, Andersen E, Bundgaard T, Primdahl H, Lambertsen K, Andersen LJ, Godballe C. Salivary gland carcinoma in Denmark 1990–2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA) Oral Oncol. 2011;47:677–682. doi: 10.1016/j.oraloncology.2011.04.020. PubMed DOI

Carlson DL. Necrotizing sialometaplasia: a practical approach to the diagnosis. Arch Pathol Lab Med. 2009;133:692–698. PubMed

Stenman G, Persson F, Andersson MK. Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol. 2014;50:683–690. doi: 10.1016/j.oraloncology.2014.04.008. PubMed DOI

Bishop JA, Yonescu R, Batista D, Eisele DW, Westra WH. Most nonparotid “acinic cell carcinomas” represent mammary analog secretory carcinomas. Am J Surg Pathol. 2013;37:1053–1057. doi: 10.1097/PAS.0b013e3182841554. PubMed DOI PMC

Löning T, Jäkel KT. Secondary tumours. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. Lyon: IARC; 2005. p. 281.

Kopeć T, Mikaszewski B, Jackowska J, Waśniewska-Okupniak E, Szyfter W, Wierzbicka M. Treatment of parotid malignancies—10 years of experience. J Oral Maxillofac Surg. 2015;73:1397–1402. doi: 10.1016/j.joms.2014.12.036. PubMed DOI

Nuyens M, Schüpbach J, Stauffer E, Zbären P. Metastatic disease to the parotid gland. Otolaryngol Head Neck Surg. 2006;135:844–848. doi: 10.1016/j.otohns.2006.05.010. PubMed DOI

Mrena R, Leivo I, Passador-Santos F, Hagström J, Mäkitie AA. Histopathological findings in parotid gland metastases from renal cell carcinoma. Eur Arch Otorhinolaryngol. 2008;265:1005–1009. doi: 10.1007/s00405-008-0679-8. PubMed DOI

Lee JS, Kwon OJ, Park JJ, Seo JH. Salivary duct carcinoma of the parotid gland: is adjuvant HER-2-targeted therapy required? J Oral Maxillofac Surg. 2014;72:1023–1031. doi: 10.1016/j.joms.2013.11.014. PubMed DOI

Metastatic cutaneous squamous cell carcinoma accounts for nearly all squamous cell carcinomas of the parotid gland